Abstract:Monoclonal antibodies are of great use in research and clinic. The first monoclonal antibody production method, hybridoma technology, was marked in the paper "Continuous cultures of fused cells secreting antibody of predefined specificity" by Milstein and Kohler in 1975 in Nature. Based on that paper, we took a retrospective and forward look of this technique. In the early research of antibodies and B cells, the low specificity and bad reproductivity of polyclonal antibodies called for new methods to produce highly specific antibodies. Fortunately, the scientists encountered the key prerequisites of the hybridoma method: (1) Mouse multiple myeloma cell lines, which can secrete antibodies and infinitely reproduce in vitro; (2) SRBC (sheep red blood cell) plates that can screen the cells secreteing anti-SRBC antibodies; (3) proper cell fusion methods like Sendai virus and PEG. Based on all these materials and methods, Milstein and Kohler fused spleen cells of immunized mice with mouse myeloma cell line P3-X67Ag8 by inactivated Sendai virus and screened to clone the fused cells that can secrete anti-SRBC antibodies. They also used HAT medium to ensure that only fused cells from spleen cells and myeloma cells can survive. In this way, they obtained the immortal cells that can produce a single type of antibody with a predefined antigen-specificity, or say, hybridoma cells that can produce monoclonal antibodies. This powerful tool of hybridoma was quickly applied and improved. Milstein and Kohler were awarded the Nobel prize and Lasker award in 1984. Despite the great commercial potential of hybridoma in medication and science research, Milstein and Kohler did not patent the method, making it free to use by anyone in the world. The monoclonal antibodies produced by hybridoma were proved highly versatile in the laboratory. Besides great insights provided to us in basic immunology research, they become the indispensable tool to precisely qualify, quantify, and localize macromolecule in all fields of research. Fluorescence imaging, Western blotting, flow cytometry and microarray methods all make use of monoclonal antibodies. Upon chimera, humanized and human monoclonal antibody development, the application and success of monoclonal antibodies on the biopharma market are even greater. Monoclonal antibody medicines to treat cancer and autoimmune diseases are making billions of dollars every year. Notably, among these medicines, anti-PD-1 and anti-CTLA-4 are awarded Nobel prize in 2018 as anti-tumor immune checkpoint inhibitors. Monoclonal antibody medicines for contagious diseases like Ebola also shows advantages over others. For the new outbreak of COVID-19 around the world, monoclonal antibodies are also promising in offering new cures. Presently, the production of monoclonal antibodies is no longer solely dependent on hybridoma technology. Transgenic and recombinant DNA technology are creating new possibilities in this ever-growing field.

Progress in the Production of Human Antibodies from Transgenic Mice and Transchromosomic Mice

Chromatographic technology in antibody purification and its progress

[Progression and direction of humanized antibody research]

Successful construction and massive expression of a novel Anti-CD19 human-mouse chimeric antibody Hm2E8b.

Construction and Expression of a Human/mouse Chimeric CD19 Monoclonal Antibody: Successful Modification of a Murine IgM to a Chimeric IgG.

Production of Antitumor Human Monoclonal Antibodies by Human-Human or Mouse-Human Hybridoma

Construction and application of huma nized immune sysetm mice

High throughput monoclonal antibody generation by immunizing multiple antigens

Construction, Expression, and Characterization of a Novel Human-Mouse Chimeric Antibody, Hm3A4: A Potential Therapeutic Agent for B and Myeloid Lineage Leukemias.

Against All Odds: the Road to Success in the Development of Human Immune Reconstitution Mice.

Monoclonal Antibodies: Emergence, Present and Outlook

Generation of Genetic Engineering Monoclonal Antibodies Against Prion Protein

Functional humanization of immunoglobulin heavy constant gamma 1 Fc domain human FCGRT transgenic mice

Application of Humanized Mice in Immunological Research.

B cell development and antibody responses in human immune system mice: current status and future perspective

Advancing Human Vaccine Development Using Humanized Mouse Models

Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery

[Xenogeneic Antigens and Immune Response in Pig to Man Xenograft].

Expression of a Recombinant Anti-Programed Cell Death 1 Antibody in the Mammary Gland of Transgenic Mice

Improved Method to Raise Polyclonal Antibody Using Enhanced Green Fluorescent Protein Transgenic Mice

Antibody Humanization By A Single Cycle Of Cdr-Grafting